Gene

FGF4

fibroblast growth factor 4

Explore in graph →CI-GENE-00001883HGNC:3682 ENSG00000075388 NCBI 2249 CIViC Approved

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGF4 Amplification2
Sorafenib	Hepatocellular Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID13273 In a retrospective analysis of sorafenib-treated hepatocellular carcinoma, FGF3/FGF4 co-amplification was detected in 3 of 10 evaluable tumors from patients with complete or partial responses and in 0… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID13275 Among 26 cancer cell lines tested for growth inhibition by sorafenib, KYSE220 was the only FGF3/FGF4-amplified cell line and showed marked sorafenib sensitivity, with an IC50 of 0.18 μM. PMID 22890726 · Arao et al., 2013 ·

Cohorts

Alteration frequency by cohort (12)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved12 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Thoracic PDX (MSK, Provisional) lung_msk_pdx	unmapped	Ssm	8	315	2.5%	129	cbioportal

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.

FGF4 Overexpression2
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID13278 A549 cells engineered to overexpress FGF4 protein formed xenografts that increased in volume more aggressively than control A549/EGFP tumors, indicating that increased FGF4 protein expression enhanced… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic
Sorafenib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID13277 In A549 xenografts engineered to stably overexpress FGF4 protein, oral sorafenib at 15 mg/kg/day significantly inhibited tumor growth relative to vehicle treatment, whereas the same low-dose regimen w… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic